Pierre Fabre has acquired the OTC business of UCB in France, Benelux, Switzerland and Greece. The acquisition includes certain mature products such as Carbolevure, Revitalose, Balsoclase, Toclase, which represent approximately $23 million in sales. UCB will continue to manufacture and supply some of the transferred products during a transitional period.

The two companies have also have entered into a distribution agreement under which Pierre Fabre will market UCB’s leading anti-histamine, ZyrtecSet, in France.

Pierre-Yves Revol, chief executive officer of Pierre Fabre commented, “The acquisition of UCB’s OTC business in these countries perfectly fits Pierre Fabre’s strategy of developing its healthcare division and enlarge its portfolio with strong brands in France, as well as in countries where the group is already well established. Both Pierre Fabre and UCB product ranges complement each other well and the addition of a new sales team will further increase our OTC presence and strengthen our ties with our pharmacy partners.”